

Diffusion Pharmaceuticals, Inc. (DFFN-NASDAQ)

DFFN: Enrollment in Phase 3 GBM Trial Continuing...

Based on our probability adjusted DCF model that takes into account potential future revenues from TSC in GBM, pancreatic cancer, and brain metastases, DFFN is valued at \$3.00/share. This model is highly dependent upon the continued clinical success of TSC and will be adjusted accordingly based upon future clinical results.

Current Price (04/19/18) **\$0.58**
Valuation **\$3.00**

OUTLOOK

Diffusion Pharmaceuticals, Inc. (DFFN) recently announced financial results for 2017 and provided a business update. The company is currently conducting the INTACT Phase 3 clinical trial of its lead candidate, trans sodium crocetin (TSC), in 236 patients with newly diagnosed inoperable glioblastoma multiforme (GBM). We anticipate an interim analysis being performed at the earlier of two years follow-up for all subjects or 198 events (deaths).

The company recently raised gross proceeds of \$12 million to help fund the trial and we anticipate the company's current cash position will be sufficient to fund operations into June 2019, however the company will need to raise additional capital in order to complete the trial.

SUMMARY DATA

52-Week High **\$3.93**
52-Week Low **\$0.50**
One-Year Return (%) **-78.83**
Beta **0.19**
Average Daily Volume (sh) **903,329**

Shares Outstanding (mil) **51**
Market Capitalization (\$mil) **\$29**
Short Interest Ratio (days) **N/A**
Institutional Ownership (%) **5**
Insider Ownership (%) **3**

Annual Cash Dividend **\$0.00**
Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates
Sales (%) **N/A**
Earnings Per Share (%) **N/A**
Dividend (%) **N/A**

P/E using TTM EPS **N/A**
P/E using 2018 Estimate **N/A**
P/E using 2019 Estimate **N/A**

Risk Level **High**
Type of Stock **Small-Value**
Industry **Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of \$)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2017	0 A	0 A	0 A	0 A	0 A
2018	0 E	0 E	0 E	0 E	0 E
2019					0 E
2020					0 E

Earnings per Share

(Diluted)

	Q1 (Mar)	Q2 (Jun)	Q3 (Sep)	Q4 (Dec)	Year (Dec)
2017	-\$2.78 A	-\$1.00 A	\$0.20 A	\$0.18 A	-\$1.94 A
2018	-\$0.06 E	-\$0.06 E	-\$0.07 E	-\$0.07 E	-\$0.26 E
2019					-\$0.26 E
2020					-\$0.28 E

WHAT'S NEW

Financial Update

On April 3, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) [announced](#) financial results for 2017 and provided a business update. For the year, the company had R&D expenses of \$5.1 million compared to \$7.3 million in 2016. The decrease was primarily due to a decrease in animal toxicology testing and stock-based compensation. G&A expenses in 2017 were \$6.2 million, compared to \$11.1 million during 2016. The decrease was primarily due to a decrease in professional fees and non-cash litigation settlement fees. In 2017, there was a \$22.1 million non-cash gain for the change in fair value of the common stock warrant liabilities.

The company exited 2017 with approximately \$8.9 million in cash and cash equivalents. In January 2018, the company [announced](#) the pricing of a \$12 million underwritten public offering of a total of 15 million shares of common stock together with 15 million warrants. The public offering price was \$0.80 per share with the warrants having an exercise price of \$0.80 and a five-year expiration date. In addition, since the company raised >\$10 million, all outstanding Series A convertible shares were automatically converted to approximately 20.6 million shares of common stock, which included shares issued for accrued dividends and for the "make-whole" adjustment feature. As of March 13, 2018, the company had approximately 50.5 million common shares outstanding and when factoring in warrants and options a fully diluted share count of approximately 84.9 million.

Business Update

Phase 3 GBM Trial Enrolling Patients

On January 29, 2018, Diffusion Pharmaceuticals, Inc. (DFFN) [announced](#) that the first patient has been dosed in the Phase 3 clinical trial of trans sodium crocetinate (TSC), a small molecule that improves diffusion of oxygen through the bloodstream in order to increase tissue oxygenation and potentially improve outcomes associated with radiation and chemotherapy cancer treatments. The trial has been named INTACT (**IN**vestigating **T**sc **A**gainst **C**ancerous **T**umors) and is anticipated to screen 300 patients with inoperable glioblastoma multiforme (GBM) and enroll 264 such that results from 236 patients will be available for analysis. Patients will be randomized 1:1 to receive TSC along with standard of care radiation and chemotherapy (temozolimide) or standard of care alone. The primary outcome of the study is overall survival at two years between the two groups. An interim analysis will take place at the earlier of a) two years follow-up for all subjects or b) 198 events (deaths). At 198 events the study will be 80% powered with an estimated overall survival time of 10 months for patients on standard of care and 14.9 months for patients treated with TSC in addition to standard of care.

The Phase 3 study is a follow up to a Phase 1/2 study of 59 GBM patients with newly diagnosed GBM ([Gainer et al., 2016](#)). In the Phase I portion of the trial, TSC was initially administered three times per week at half-dose to three patients prior to radiation. Six additional patients received full dose TSC for six weeks in combination with radiation. No dose-limiting toxicities were identified in the nine patients during the Phase I portion of the trial. Fifty additional patients were enrolled in the Phase II trial at full dose TSC in combination with TMZ and RT. Four weeks after completion of RT, all patients resumed TMZ for five days every four weeks, but no further TSC was administered.

The results of the study were presented in relation to a historical control group, which is from a 2005 study that showed the addition of TMZ to standard of care (surgery plus radiation) increased overall survival from 12.1 months to 14.6 months ([Stupp et al., 2005](#)). Diffusion reported that:

- ❖ TSC plus radiation and TMZ increased the patients' chance of survival at two years by 37% compared to the historical control group. The overall survival at two years was 37% in the TSC group compared to 27% in the historical control group.
- ❖ In the subgroup of patients considered inoperable (biopsy only), the chance of survival at two years for those who received TSC was increased by 380%.
- ❖ 71 percent of people treated with TSC were alive at one year compared to 61 percent of people in the historical control group.

- ❖ Of the 37 patients with tumors able to be monitored, 27 experienced tumor regression, with 11 (30%) patients having complete tumor regression.
- ❖ No serious negative safety findings attributed to TSC were observed in the TSC study and adverse events were consistent with those seen in previous trials of GBM featuring radiation and TMZ.

Since the study lacked a control arm it is difficult to draw definitive conclusions regarding the activity of TSC, however we have been unable to identify another publication that discusses tumor regression in GBM patients, thus it is difficult to put this data fully into context. Gainer *et al.* cite anecdotal evidence of a maximum regression of 25% typically seen with standard RT through discussions with those who administer RT to GBM patients, thus 30% of patients experiencing complete tumor regression appears to be unprecedented.

Planning Underway for Phase 2 Trial in Stroke Patients

On January 24, 2018, Diffusion [announced](#) the acceptance of an abstract titled “PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC)” which was presented at the International Stroke Conference Jan. 24-26, 2018. The abstract discusses the design and rationale for a planned Phase 2 study of TSC in patients with acute ischemic (from a clot) or hemorrhagic (from a bleed) stroke. It will be a randomized, double blind, placebo controlled trial with an anticipated enrollment of 160 ambulance-transported patients treated within two hours of the onset of a suspected stroke. If funding allows for the trial to begin in 2018, results could be available in 2019.

Preclinical models show that TSC could be an effective treatment for both ischemic and hemorrhagic stroke ([Wang et al., 2014](#)). In a rat model of ischemia-reperfusion, which involved two hours of ischemia followed by 22 hours of reperfusion, treatment with TSC one and a half hours after onset of ischemia led to a significant reduction in infarct volume of 32%. In a second model of ischemia-reperfusion, which involved two hours of reperfusion followed by an additional four hours of one vessel occlusion, treatment with TSC significantly reduced infarct volume by 34%. Lastly, in an intracerebral hemorrhage model in which TSC was administered three hours after collagenase injection, there was a significant reduction in hemispheric swelling and hemorrhage volume in animals treated with TSC. It is important that TSC be effective, or at least not detrimental, regardless of the type of stroke. Otherwise, its use would be contraindicated prior to the diagnosis of the type of stroke and by that time it may be too late to be effective.

There are approximately 800,000 strokes every year in the U.S., and they are responsible for the deaths of approximately 140,000 individuals (CDC). Strokes cost the U.S. healthcare system an estimated \$34 billion every year ([Benjamin et al., 2017](#)). The only FDA approved treatment for acute ischemic stroke is tissue plasminogen activator (t-PA), although its use can aggravate outcomes in hemorrhagic stroke and increase hemorrhagic transformation in some ischemic strokes ([Larrue et al., 2001](#)). Worldwide sales of alteplase (recombinant t-PA) totaled \$1.4 billion in 2016 and is expected to grow to \$1.9 billion by 2022 (EvaluatePharma).

Valuation

Diffusion’s valuation is derived from a risk-adjusted discounted cash flow model that takes into account potential future revenues from the sale of TSC in GBM, pancreatic cancer, and brain metastases. For all indications we assume that the company will partner and receive 15% royalties on net sales.

For GBM, we model for a new drug application (NDA) to be filed in 2021, and approval in 2022. For pancreatic cancer, we model for the Phase 2 trial to initiate in 2019, an NDA filing in 2022, and approval in 2023. For brain metastases, we model for a Phase 2/3 trial to initiate in 2020, an NDA filing in 2023 and approval in 2024.

Combing the net present value for each of the company’s development programs along with the company’s current cash position and estimated additional capital necessary leads to a valuation of \$3.00 per share. The stock is currently trading at a significant discount to this valuation and we believe that investors could use the current downturn to add to or establish a position.

PROJECTED FINANCIALS

Diffusion Pharmaceuticals, Inc.	2017 A	Q1 E	Q2 E	Q3 E	Q4 E	2018 E	2019 E	2020 E
TSC (GBM)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
TSC (Pancreatic Cancer)	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
Grants & Collaborative Revenue	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
Total Revenues	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
Cost of Sales	\$0	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>Product Gross Margin</i>	-	-	-	-	-	-	-	-
Research & Development	\$5.1	\$1.5	\$1.8	\$2.0	\$2.2	\$7.5	\$9.0	\$11.0
General & Administrative	\$6.2	\$1.4	\$1.5	\$1.5	\$1.6	\$6.0	\$6.5	\$7.0
Depreciation	\$0.1	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0
Operating Income	(\$11.3)	(\$2.9)	(\$3.3)	(\$3.5)	(\$3.8)	(\$13.5)	(\$15.5)	(\$18.0)
<i>Operating Margin</i>	-	-	-	-	-	-	-	-
Non-Operating Expenses (Net)	\$8.9	\$0.0	\$0.0	\$0.0	\$0.0	\$0.0	(\$0.2)	(\$0.2)
Pre-Tax Income	(\$2.4)	(\$2.9)	(\$3.3)	(\$3.5)	(\$3.8)	(\$13.5)	(\$15.7)	(\$18.2)
Income Taxes Paid	(\$1)	\$0	\$0	\$0	\$0	\$0	\$0	\$0
Accretion of Series A preferred dividends	(\$1)	\$0	\$0	\$0	\$0	\$0	\$0	\$0
<i>Tax Rate</i>	0%	0%	0%	0%	0%	0%	0%	0%
Net Income	(\$2.6)	(\$2.9)	(\$3.3)	(\$3.5)	(\$3.8)	(\$13.5)	(\$15.7)	(\$18.2)
<i>Net Margin</i>	-	-	-	-	-	-	-	-
Reported EPS	(\$0.21)	(\$0.06)	(\$0.06)	(\$0.07)	(\$0.07)	(\$0.26)	(\$0.26)	(\$0.28)
<i>YOY Growth</i>	-	-	-	-	-	-	-	-
Basic Shares Outstanding	12.4	50.5	51.0	52.0	53.0	51.6	60.0	65.0

Source: Zacks Investment Research, Inc.

David Bautz, PhD

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research (“Zacks SCR”), a division of Zacks Investment Research (“ZIR”), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, David Bautz, PhD, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer’s business. SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.